BACKGROUND: In circulating lymphocytes of individuals with insulin resistance and overt hyperglycaemia (NIDDM patients), alterations, affecting pyruvate dehydrogenase (PDH), the key enzyme in glucose oxidative breakdown, have been observed. They include below normal enzyme activity and, in vitro, no enzyme response to insulin at low physiological levels (5 m mUaml) as well as activation up to the basal values of controls with insulin at high physiological levels (50 m mUaml), instead of activation and inhibition respectively, as in controls. OBJECTIVE: To investigate whether these alterations characterize circulating lymphocytes of individuals with insulin resistance in whom derangements of glucose homeostasis are absent (obese subjects with normal glucose tolerance), or present but still controllable (nonobese and obese newly diagnosed NIDDM patients on an appropriate diet). SUBJECTS: Thirty obese subjects (BMI 36 AE 3) responding normally to an oral glucose tolerance (OGT) test; 60 newly diagnosed NIDDM patients (30 nonobese, BMI 22 AE 4 and 30 obese, BMI 38 AE 2); 30 nonobese (BMI 21 AE 5) and nondiabetic subjects, with no family history for NIDDM, served as controls. METHODS: Evaluation of PDH activity in circulating lymphocytes before and after exposure to insulin at 5 and 50 m mUaml, and of clinical parameters before and during an OGT test. RESULTS: 1) In circulating lymphocytes of obese nondiabetic subjects as well as obese and nonobese newly diagnosed NIDDM patients, PDH activity was signi®cantly below normal. In vitro, enzyme response to insulin at 5 m mUaml was reduced in nonobese NIDDM patients with respect to controls, and absent in obese nondiabetic subjects and obese NIDDM patients. Enzyme response to insulin at 50 m mUaml was reversed in all individuals, which allowed enzyme activity to recover up to the basal level of controls. 2) In NIDDM patients and obese nondiabetic subjects, undergoing an OGT test, the area under the glycaemic curve (g-AUC) was as expected; the area under the insulinaemic curve (i-AUC) was increased in both groups with respect to controls, but signi®cantly only in the latter. CONCLUSION: In individuals with insulin resistance PDH activity in their circulating lymphocytes rises up to basal levels of controls, only if these cells are exposed to insulin at high physiological concentrations, and g-AUC is normal only in those subjects who have signi®cantly increased i-AUC. This suggests that with insulin at suf®ciently high concentrations both parameters can be corrected. We conclude that the derangements responsible for the alterations of the two parameters share common features and thus the described PDH alterations in circulating lymphocytes re¯ect systemic insulin resistance whether accompanied by hyperglycaemia or not.
Introduction
A reduced activity of pyruvate dehydrogenase (PDH), the rate limiting enzyme in glucose breakdown through oxidative pathways, characterizes circulating lymphocytes of normal-weight patients with overt NIDDM. 1 In vitro, in these cells insulin at high physiological concentrations (50 mUaml) evokes PDH activation, whereas at low physiological ones (5 mUaml) it is ineffective. 1 In similarly treated cells of age-matched healthy subjects, with no family history for the disease, inhibition and activation, respectively, take place. 1±3 This study investigates whether such enzyme alterations also characterize circulating lymphocytes of individuals with insulin resistance, in whom derangements of glucose homeostasis are absent (obese subjects with normal glucose tolerance) or, if present, are still controllable (nonobese and obese newly diagnosed NIDDM patients on a controlled diet).
To better understand the planning of this study, some characteristic properties of PDH are brie¯y described here. In mammalian tissues PDH exists in a polymeric form (PDC), the catalytic activity of which is modulated by the reaction products (NADH and acetylCoA) which behave as inhibitors and by structural covalent modi®cations. The latter depend on the fact that one of the complex components, the regulatory subunit, exists in a balance between two forms, phosphorylated inactive (PDHb) and dephosphorylated active (PDHa). The interconversion is controlled by a kinase (PDH kinase), which is active in the presence of ATP, stimulated by mM Mg 2 and inhibited by mM dichloroacetate, and by a phosphatase (PDHP phosphatase), which is activated by mM Ca 2 and mM Mg 2 , inhibited by mM NaF 4 and considered the actual insulin target.
5±12 PDH activity can thus be expressed in terms of PDC in the active form (PDHa), or in terms of PDC total activity (PDHt), tested in experimental conditions allowing full conversion of PDHb into PDHa.
Methods

Subjects
The case series of this study included: 1) 60 newly diagnosed NIDDM individuals 13 (35 male and 25 female, 30 obese and 30 nonobese), in whom an appropriate diet was still suf®cient to maintain satisfactory glycaemic control; 2) 30 obese subjects (14 male, 16 female) with normal glucose tolerance, assessed through an oral glucose tolerance (OGT) test, performed according to National Diabetes Data Group (NDDG) recommendations, 13 who had been on an unrestricted diet for 3 months; 3) 30 healthy nonobese subjects (15 male, 15 female), without a family history for NIDDM, served as controls. In obese nondiabetic subjects and obese NIDDM patients, a complete medical work-up was performed to exclude the possibility that overweight was due to endocrine disorders.
Clinical and haematological parameters of NIDDM patients and obese nondiabetic subjects are summarized in Table 1 .
None of the obese and nonobese NIDDM patients had undergone pharmacological treatment for their condition and none had taken, during the last 3 months, drugs that could affect glucose tolerance. 
Lymphocyte preparation
Blood samples were collected, in fasting conditions, in disposable vials, containing 10% EDTA pH 7.4 (1 mla10 ml blood) and diluted 1:1 with 156 mM NaCl. Lymphocyte preparation was performed according to Boyu Èm.
14 At the end of preparation, cells were suspended in 110 mM NaCl buffered in 40 mM Na 2 HPO 4 -KH 2 PO 4 pH 7.4 (PBS-A) and identi®ed by morphological, biochemical and immunological techniques. 3 In all preparations the cell suspension consisted of 89±93% lymphocytes. Monocytes were no more than 0.2±2.5%.
One part of the cell preparation was used immediately for insulin contact procedures, another part for lymphocyte counts performed manually by means of a haemocytometer. The remaining cells were pelletted, suspended in PBS-A enriched with 2 mgaml leupeptin and 20 mM EDTA (PBS-B), stored at 770 C and ®nally used for evaluation of PDH activity. PDH activity was evaluated using lymphocytes which had been lysed by cryolysis, followed by sonication at 4 C and then incubated in experimental conditions either blocking conversion of PDHa into PDHb and vice versa, or determining total conversion of PDHb into PDHa. 4 Lysed cells were incubated in a ®nal volume of 100 ml, with 20 mg albumin, 10 mM TrisHCl pH 8, 1 mM DTT with either: a) 50 mM NaF, 1 mM dichloroacetate, 4, 15 used for testing the activity of PDC already in the active form (i.e. as PDHa); or b) 50 mM CaCl 2 , 10 mM MgCl 2 and excess of PDHP phosphatase, puri®ed from bovine heart according to Teague et al 16 up to step H, used for testing the PDC activity resulting from full conversion of PDHb into PDHa, and thus expression of PDC total activity (PDHt). After 10 min at 37 C, samples for the assay of PDHa activity were supplemented with MgCl 2 , so that all samples would have the same ®nal Mg 2 concentration. The reagents for the assay of PDH activity, consisting of 1 mM CoA, 1 mM NAD , 20 mM cysteine, 20 mM pyruvate, 80 mM phosphate buffer pH 8, 0.1U lactic dehydrogenase and excess of phosphotransacetylase in a ®nal volume of 250 ml, were then added to all samples. The reaction was left to go on for 30 min at 37 C and then stopped with 6% HClO 4 . Deproteinized samples were neutralized at pH 7.4 and then tested for the acetyl phosphate formed, according to Allred and Guy. 17 
Cell incubation
Exposure of circulating lymphocytes to insulin was performed using intact fresh cells suspended in PBS-A (2±3610 6 cellsaml) and incubated in a ®nal volume of 200 ml, with insulin at 5 or 50 mUaml, in a medium containing 10 mM phosphate buffer pH 7.4, 20 mg BSA and 50 mM CaCl 2 and MgCl 2 .
1±3 After 15 min at 37 C, cells were added with 1ml PBS-A centrifuged, washed twice with PBS-A, suspended in PBS-B, frozen at 770 C and ®nally used for PDH activity assay. Control samples, in which insulin was omitted, were run in parallel.
Cell viability at the end of incubation procedures was close to 98%.
Statistical analysis
Statistical analysis was performed using ANOVA, Student's t test for paired and unpaired data, Turkey and Newman-Keuls for multiple comparison test as appropriate for each case. P`0.05 was taken as the criterion of signi®cance.
Results
Clinical data of the obese nondiabetic subjects (30) , nonobese (30) and obese (30) newly diagnosed NIDDM patients and controls (30) are reported in Table 1 .
In circulating lymphocytes of all NIDDM patients, whether obese or not, and of obese nondiabetic subjects PDH activity was signi®cantly lower in terms of PDHa, but not signi®cantly different in terms of PDHt, when compared to cells of controls (Table 2) .
Incubation with insulin at 50 mUaml of circulating lymphocytes from nonobese and obese NIDDM patients and from obese nondiabetic subjects, was followed by an increase of PDH activity, close to the basal levels of unstimulated cells of controls. In similarly exposed cells of controls PDH was clearly inhibited (Table 3 ). Exposure to insulin at 5 mUaml of circulating lymphocytes from controls, obese nondiabetic subjects and obese NIDDM patients, caused a sharp increase in PDH activity in cells from controls, but no response in the other two groups. In nonobese NIDDM patients PDH response to insulin at 5mUaml was blunted, in that enzyme activity rose signi®cantly, but remained below the levels in unstimulated cells of controls (Table 3) .
Discussion
In circulating lymphocytes of obese subjects with normal glucose tolerance, newly diagnosed obese, as well as nonobese NIDDM patients on a restricted diet, basal and insulin stimulated PDH activities re¯ect the alterations observed in these cells of patients with overt NIDDM (See Introduction).
The derangements should not be due to a quantitative enzyme defect, since in obese nondiabetic subjects, as well as obese and nonobese NIDDM patients, PDHt is comparable to that of controls. Reduced PDHa activity with unvaried PDHt in various tissues of animals with experimental diabetes and obese hyperinsulinaemic rats has been reported. 5, 6, 18, 19 From the above, low PDHa activity might be explained if the conversion rate of PDHa into PDHb were shifted in favour of PDHb. Increased fatty acid oxidation, responsible for increased mitochondrial ATPaADP, acetyl CoAaCoA and NADHaNAD , with ensuing increased conversion of PDHa into PDHb following activation of PDH kinase, could contribute to lower PDHa activity. 20±28 Although serum triglycerides and free fatty acid concentrations can be expected to affect PDH activity only indirectly, in nonobese NIDDM patients serum triglycerides are at the upper limit of normality and in obese NIDDM patients they are often above this limit (Table 1) . On the other hand, in obese nondiabetic subjects serum triglycerides, together with free fatty acids, are normal (Table 1 ) and thus in these individuals they should not be responsible for the low enzyme activity.
If PDHP phosphatase were defective, the resulting defective conversion of PDHb into PDHa would contribute to low PDHa activity. Furthermore, since the phosphatase is well documented to be under insulin control, 5±12 were it defective, it would contribute to the deranged PDH response to insulin at 5 mUaml (Table 3) . However, exposure of circulating lymphocytes from obese nondiabetic subjects and obese and nonobese NIDDM patients to insulin at 50m Uaml produced a rapid rise of PDHa activity up to the basal level of controls, suggesting that the phosphatase itself is not primarily impaired. Insulin effects on PDH are observed only when intact cells are used, 1±3 supporting the view that the plasma membrane is essential for insulin to be effective on PDHP phosphatase, in line with different reports on a variety of cells and tissues. 29±35 Thus the plasma membrane might be the site where PDH alterations originate. If so, low PDH activity in individuals who have impaired PDH response to insulin at 5 mUaml, and reversed response to insulin at 50 mUaml associated with recovery of enzyme activity, would ®nd an explanation since, in fasting conditions, their insulinaemia is well below 50 mUaml.
In circulating lymphocytes of healthy subjects, in vitro, insulin at concentrations above and below 5 mUaml is progressively less effective (around 10 and below 2.5 mUaml it is no longer effective) in raising enzyme activity.
1±3 Possibly this explains why, in vitro, exactly at 5 mUaml insulin determines signi®cantly higher enzyme activity than in vivo where, although its mean value is 6 mUaml, it actually varies in the range 3±9 mUaml (Table 1) . Furthermore, in vitro, besides being washed, cells are exposed to insulin alone, whereas, in vivo, insulin action is likely to be countered by compounds known to be insulin antagonists (for example, glucagon, growth hormone, adrenaline, glucocorticoids). The effects of such compounds could explain why in individuals, in whom insulin has dif®culties in controlling PDH, enzyme activity is below normal.
Obese subjects subjected to an OGT test have a normal g-AUC and a signi®cantly increased i-AUC (Table 1) . Newly diagnosed NIDDM patients, whether obese or not, have an abnormal g-AUC and an increased (but not signi®cantly) i-AUC (Table 1 ). In circulating lymphocytes of all these individuals exposed to insulin at 50 mUaml, PDH response is reversed and enzyme activity rises, thereby reaching the basal value of controls. Thus, in subjects with systemic insulin resistance, the underlying derangements responsible for PDH alterations in circulating lymphocytes and for increased g-AUC, share the common feature of being overcome by insulin if at suf®ciently high concentrations. This supports the conclusion that derangements of PDH in circulating lymphocytes re¯ect systemic insulin resistance. If so, it is surprising that enzyme response to insulin at 5 mUaml is suppressed in obese nondiabetic subjects and only blunted in nonobese NIDDM patients, who instead, have alterations of glucose homeostasis. Little is known whether the role of PDH in circulating lymphocytes is an expression of the role this enzyme plays in tissues involved in preserving glucose homeostasis and results of this study are far from conclusive concerning this issue. However, in obese NIDDM patients PDH activity is below normal in skeletal muscle, 36 whereas in adipocytes of these patients it is normal, although in vitro in these cells enzyme response to insulin is sharply altered. 37 Also in adipocytes of obese nondiabetic individuals PDH activity is normal 37 or even above normal, 38 despite impaired enzyme response to insulin in vitro. 37 Since PDH is the major determinant of glucose consumption along oxidative pathways, tissues in which PDH activity is low, should contribute to the onset of hyperglycaemia, whereas tissues in which this is not so, would not. In this view, obese nondiabetic subjects, with their overdeveloped fat mass, will counter hyperglycaemia relatively ef®ciently, particularly since PDH is also a rate limiting factor in the conversion of glucose into free fatty acids. Furthermore, the relatively high blood insulin levels these subjects are 39 It is possible that in obese nondiabetic subjects, the above suggested parallel between PDH derangements in circulating lymphocytes and systemic insulin resistance is masked by the prevalence of a tissue in which PDH activity is normal. Newly diagnosed nonobese NIDDM patients obviously do not have this option. Thus, even less severe systemic insulin resistance, as suggested by only blunted enzyme response to insulin at 5 mUaml, because uncountered, would put them on the verge of overt diabetes. These patients will have a suppressed enzyme response to insulin at 5 mUaml when they develop overt diabetes (see Introduction), since presumably systemic insulin resistance worsens. Obese subjects, in whom this response is already suppressed, will become NIDDM patients when insulin availability diminishes. In fact, in newly diagnosed obese NIDDM patients the enzyme response to insulin at 5 mUaml is suppressed, but, differently from obese nondiabetic subjects and similarly to their nonobese counterparts, i-AUC is not signi®cantly increased.
